Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial

BACKGROUND: Tiludronate and clodronate are FDA-approved bisphosphonate drug therapies for navicular disease in horses. Although clinical studies have determined their ability to reduce lameness associated with skeletal disorders in horses, data regarding the effect on bone structure and remodeling i...

Descripción completa

Detalles Bibliográficos
Autores principales: Richbourg, Heather A., Mitchell, Colin F., Gillett, Ashley N., McNulty, Margaret A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859757/
https://www.ncbi.nlm.nih.gov/pubmed/29554967
http://dx.doi.org/10.1186/s12917-018-1423-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859757/
https://www.ncbi.nlm.nih.gov/pubmed/29554967
http://dx.doi.org/10.1186/s12917-018-1423-2

Ejemplares similares